Literature DB >> 1359487

Localization of alpha-2 adrenergic receptors in the human eye.

T Matsuo1, M S Cynader.   

Abstract

To elucidate sites of the action of alpha-2 adrenergic drugs, we localized binding sites for a potent alpha-2 adrenergic agonist, UK-14,304, in sections of the human cadaveric eye by an in vitro ligand-binding technique and autoradiography. Its specific binding sites were found in the iris epithelium and ciliary epithelium at a high level, and also in the ciliary muscle, retina, retinal pigment epithelium (and/or choroid). Binding of UK-14,304 to the ocular pigments was prevented by preincubating the eye sections with chloroquine, which reduced the non-specific binding to a low level.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359487     DOI: 10.1159/000267170

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  16 in total

1.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

2.  [The effect of brimonidine on the pupillary reflex. A pupillographic study in healthy volunteers].

Authors:  S Dinslage; B Strauss; J F Jordan; M Diestelhorst; G K Krieglstein
Journal:  Ophthalmologe       Date:  2005-09       Impact factor: 1.059

3.  Topical mydriatics affect light-evoked retinal responses in anesthetized mice.

Authors:  Deb Kumar Mojumder; Theodore G Wensel
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

Review 4.  Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.

Authors:  Elma E Chang; Jeffrey L Goldberg
Journal:  Ophthalmology       Date:  2012-02-18       Impact factor: 12.079

Review 5.  Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection.

Authors:  F B Kalapesi; M T Coroneo; M A Hill
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

Review 6.  Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.

Authors:  J C Adkins; J A Balfour
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

7.  The effect of brimonidine on transepithelial resistance in a human retinal pigment epithelial cell line.

Authors:  Jung Hyun Park; Sung Joon Kim; Hyeong Gon Yu
Journal:  Korean J Ophthalmol       Date:  2010-06-05

8.  Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells.

Authors:  Kelvin Yoon Chiang Lee; Mao Nakayama; Makoto Aihara; Yi-Ning Chen; Makoto Araie
Journal:  Mol Vis       Date:  2010-02-17       Impact factor: 2.367

9.  Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly(lactic acid) microspheres for the treatment of glaucoma.

Authors:  B Chiang; Y C Kim; A C Doty; H E Grossniklaus; S P Schwendeman; M R Prausnitz
Journal:  J Control Release       Date:  2016-02-28       Impact factor: 9.776

10.  The Multitarget Ligand 3-Iodothyronamine Modulates β-Adrenergic Receptor 2 Signaling.

Authors:  Juliane Dinter; Noushafarin Khajavi; Jessica Mühlhaus; Carolin Leonie Wienchol; Maxi Cöster; Thomas Hermsdorf; Claudia Stäubert; Josef Köhrle; Torsten Schöneberg; Gunnar Kleinau; Stefan Mergler; Heike Biebermann
Journal:  Eur Thyroid J       Date:  2015-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.